Gesynta Pharma Randomizes 50% of Patients in Phase 2 Endometriosis Trial of Vipoglanstat
Summary
Gesynta Pharma says it has randomized half of the 190 patients planned for its Phase 2 NOVA trial in endometriosis. The company is testing vipoglanstat, an oral non-hormonal and non-opioid candidate, across multiple sites in Europe. Management says the enrollment pace has been strong and ahead of schedule, and it expects top-line results in 2027. The trial data will help shape a later Phase 3 program and further development of the drug candidate.
Classifications
industries
No industries detected
applications
Accounting and Taxes
AskAI Classifications
Labels
SaaS
Media Intelligence Software
Marketing Technology
Linked Companies
Cision Ltd.
$500M to $1B